All stock reports

AAREYDRUGS evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • Financial data quality flags require resolution.
  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-08-25T23:17:16.162837+00:00

Metrics

latest_annual_period
2026-03-31
revenue
4722690000.0
net_income
39676000.0
operating_cash_flow
-109807000.0
free_cash_flow
-233915000.0
total_assets
2972467000.0
total_liabilities
1468235000.0
total_equity
1504232000.0
cash
33980000.0
total_debt
499616000.0
revenue_growth
-0.0035327010636082568
earnings_growth
-0.013991401376773793
net_margin
0.008401144263121229
roe
0.02637625047200166
debt_to_equity
0.33214025496067096
cash_conversion
-2.767592499243875
free_cash_flow_margin
-0.04953003478949497
trailing_pe
Not supplied
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Breakout Volatility Expansion

Research only. Direction: LONG.

Tests range escape confirmed by participation expansion

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
False breakout back into range
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-c1fe213df4a4a9fcc81bb0ba64fc732018ced751497786ec7af7dcc0d3bc518e
Policy
stock-decisions-v1
Evidence bundle hash
f3a0b417f00dfe9d5f00f3e7b9c6354e18e00ad7caa550146f6ad512a92a2faf
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 21897afb111eb89916a1dfe92c91725aa17547bac8eeabf078381b9ad593946d
  • daily-price: db50db43bb4c0e76d04dc341f6a47a1ff5e607b8a8e82fce6a467ea66fdd68d5
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The cached closing price on 2026-10-01 was INR 103.85. The trailing 5-session price return was 3.58%. The trailing 20-session price return was 13.23%. The trailing 60-session price return was 20.42%. The trailing 250-session price return was 37.20%.

Risks

The cached financial metric cash conversion is -2.767592499243875. The cached financial metric free cash flow margin is -0.04953003478949497. Financial data check: weak_cash_conversion: operating cash flow/net income below 0.5.

Follow Up

The cached financial metric latest annual period is 2026-03-31. Average cached traded value over twenty sessions was INR 23,118,329. The closing price was 0.00% below its highest close in the available trailing year.

Cached observations and evidence limits